Trials / Completed
CompletedNCT01719549
Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1
A Phase II Trial of Dovitinib Monotherapy as Salvage Treatment in Patients With Metastatic or Unresectable Gastric Cancer Harboring FGFR2(Fibroblast Growth Factor Receptor 2) Amplification After Failure of First or Second Line Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, prospective, single-arm, open-label phase II study
Detailed description
In this study, we will evaluate the efficacy and safety of TKI258(Dovitinib) monotherapy as a salvage chemotherapy after failure of standard first or second-line chemotherapy in metastatic or unresectable gastric cancer harboring FGFR2 amplification.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dovitinib | * Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule * Study drug: TKI258 capsule * Dose: 500mg p.o. qd * Every 3 weeks |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2016-02-01
- Completion
- 2016-11-01
- First posted
- 2012-11-01
- Last updated
- 2020-01-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01719549. Inclusion in this directory is not an endorsement.